HIGHBuilt-in & outside partyProduct / Revenue mix
MYQORZO
“10-K Item 1: 'Our first commercial product is MYQORZO™ (aficamten)...which the FDA approved in December 2025'”
CYTK · Concentration risk · 10-K extracted
Cytokinetics (CYTK) concentration risks
Updated
The most significant concentration Cytokinetics discloses is MYQORZO, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Cytokinetics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
single source CMOs
“10-K Item 1A: 'We currently rely on single source CMOs for the manufacture of any or all of MYQORZO as a finished drug product and the active pharmaceutical ingredient'”
HIGHBuilt-inPipeline
ACACIA-HCM
“10-K Item 1: 'Aficamten continues to be evaluated in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with nHCM'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is defined by three interconnected high-share exposures that collectively reflect the typical structure of a single-asset commercial-stage biopharmaceutical company. The company's first commercial product, MYQORZO (aficamten), received FDA approval in December 2025, making it the sole source of near-term commercial revenue and the anchor of the entire business model. This product concentration is the most fundamental risk in the profile: all near-term revenues are tied to the commercial uptake of a single molecule across its approved indication. Compounding that product dependency is a manufacturing concentration. The company currently relies on single-source contract manufacturing organizations for both the finished drug product and the active pharmaceutical ingredient for MYQORZO. This is a high-share dependency by disclosed size; any disruption at a sole-source CMO — whether operational, regulatory, or contractual — could constrain supply and directly impair the commercial ramp at precisely the moment revenue visibility is being established. Layered on top is a pipeline concentration. Aficamten continues to be evaluated in the ACACIA-HCM Phase 3 clinical trial, meaning the company's medium-term growth optionality is also tied to a single molecule. The three exposures do not diversify each other — they are all aficamten-dependent in different time horizons. On balance, the profile is tightly concentrated along one asset, with manufacturing and pipeline risks amplifying the product risk rather than offsetting it.
For the engine’s reasoning on CYTK’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| CYTK● | Cytokinetics, Incorporated | 3 | 0 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.